Vpx-containing dendritic cell vaccine induces CTLs and reactivates latent HIV-1 in vitro

Gene Therapy

Volumn 22, Issue 3, 2015, Pages 227-236

  Norton, T D ^a,b   Miller, E A ^b   Bhardwaj, N ^b   Landau, N R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; DENDRITIC CELL VACCINE; EPITOPE; LENTIVIRUS VECTOR; NEVIRAPINE; RALTEGRAVIR; TUMOR NECROSIS FACTOR ALPHA; CD40 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESERVOIR; SIGNAL TRANSDUCTION; VIRUS REACTIVATION; CELL CULTURE; DENDRITIC CELL; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LENTIVIRINAE; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIGENS, CD40; CELLS, CULTURED; DENDRITIC CELLS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS LATENCY;

EID: 84924599616     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.117     Document Type: Article

References (49)

1. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39: 38-48.
2. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
3. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 1998; 9: 457-463.
4. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011; 480: 379-382.
5. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012; 13: 223-228.
6. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474: 658-661.
7. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474: 654-657.
8. Sunseri N, O'Brien M, Bhardwaj N, Landau NR. Human immunodeficiency virus type 1 modified to package Simian immunode ficiency virus Vpx efficiently infects macrophages and dendritic cells. J Virol 2011; 85: 6263-6274.
9. Bobadilla S, Sunseri N, Landau NR. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. Gene Therapy 2012; 20: 514-520.
10. Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol 1991; 147: 4047-4053.
11. Koya RC, Kasahara N, Favaro PM, Lau R, Ta HQ, Weber JS et al. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 2003; 26: 451-460.
12. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth Jr RJ. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161: 2094-2098.
13. Tureci O, Bian H, Nestle FO, Raddrizzani L, Rosinski JA, Tassis A et al. Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J 2003; 17: 836-847.
14. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukocyte Biol 2000; 67: 2-17.
15. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-1272.
16. de Saint-Vis B, Fugier-Vivier I, Massacrier C, Gaillard C, Vanbervliet B, Ait-Yahia S et al. The cytokine pro file expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160: 1666-1676.
17. Gray D, Siepmann K, Wohlleben G. CD40 ligation in B cell activation, isotype switching and memory development. Sem Immunol 1994; 6: 303-310.
18. Fonteneau JF, Larsson M, Somersan S, Sanders C, Munz C, Kwok WW et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods 2001; 258: 111-126.
19. Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 1994; 180: 1283-1293.
20. Adnan S, Balamurugan A, Trocha A, Bennett MS, Ng HL, Ali A et al. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 2006; 108: 3414-3419.
21. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
22. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86: 2365-2368.
23. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22: 1868-1877.
24. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
25. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ t cells from aviremic patients. PLoS Pathogens 2013; 9: e1003834.
26. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and posttranscriptional mechanisms. J Exp Med 1990; 172: 151-158.
27. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, Acheampong EA et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115: 128-137.
28. Durand S, Nguyen XN, Turpin J, Cordeil S, Nazaret N, Croze S et al. Tailored HIV-1 vectors for genetic modification of primary human dendritic cells and monocytes. J Virol 2013; 87: 234-242.
29. Negri DR, Rossi A, Blasi M, Michelini Z, Leone P, Chiantore MV et al. Simian immunode ficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. Retrovirology 2012; 9: 69.
30. Tareen SU, Kelley-Clarke B, Nicolai CJ, Cassiano LA, Nelson LT, Slough MM et al. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Mol Ther 2013; 22: 575-587.
31. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142.
32. Auten MW, Huang W, Dai G, Ramsay AJ. CD40 ligand enhances immunogenicity of vector-based vaccines in immunocompetent and CD4+ T cell deficient individuals. Vaccine 2012; 30: 2768-2777.
33. Dybul M, Mercier G, Belson M, Hallahan CW, Liu S, Perry C et al. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness. J Immunol 2000; 165: 1685-1691.
34. Zhang R, Zhang S, Li M, Chen C, Yao Q. Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010; 28: 5114-5127.
35. Kutsch O, Levy DN, Kosloff BR, Shaw GM, Benveniste EN. CD154-CD40-induced reactivation of latent HIV-1 infection. Virology 2003; 314: 261-270.
36. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001; 19: 3280-3287.
37. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013; 254: 170-189.
38. Miller EA, Spadaccia MR, O'Brien MP, Rolnitzky L, Sabado R, Manches O et al. Plasma factors during chronic HIV-1 infection impair IL-12 secretion by myeloid dendritic cells via a virus-independent pathway. J Acquir Immune Defic Syndr 2012; 61: 535-544.
39. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013; 381: 2109-2117.
40. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
41. Firat H, Tourdot S, Ureta-Vidal A, Scardino A, Suhrbier A, Buseyne F et al. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A∗0201 transgenic, H-2 class I KO mice. Eur J Immunol 2001; 31: 3064-3074.
42. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PloS One 2009; 4: e6529.
43. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cellmediated lysis. J Exp Med 1991; 174: 489-492.
44. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22: 589-594.
45. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
46. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol 1989; 142: 431-438.
47. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L et al. Sensitivity of human immunode ficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74: 8358-8367.
48. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 2009; 83: 8289-8292.
49. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-1905.